NEW YORK, March 7, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
INSYS Therapeutics, Inc. (NASDAQ: INSY), Oxygen Biotherapeutics,
Inc. (NASDAQ: OXBT), Acorda Therapeutics, Inc. (NASDAQ: ACOR), Air
Methods Corp. (NASDAQ: AIRM), and AcelRx Pharmaceuticals, Inc.
(NASDAQ: ACRX). Private wealth members receive these notes ahead of
publication. To reserve complementary membership, limited openings
are available at: http://www.AnalystsReview.com/register
--
INSYS Therapeutics, Inc. Analyst
Notes
On March 4, 2014, INSYS
Therapeutics, Inc. (Insys) reported its Q4 2013 and full-year 2013
financial results. For the quarter, total net revenue grew to
$40.2 million compared to
$5.2 million in Q4 2012. Net income
for the quarter totaled $24.1 million
or $1.01 per diluted share compared
to a net loss of $7.1 million or
$0.76 per diluted share in Q4 2012.
For full year 2013, total net revenue was $99.3 million compared to $15.5 million in full year 2012. Annual net
income totaled $40.4 million or
$2.11 per diluted share compared to a
net loss of $24.4 million or
$2.62 diluted share in full year
2012. Michael L. Babich, President
and CEO, commented, "Our solid results for the quarter and year
were driven by strong growth in Subsys prescriptions to alleviate
breakthrough pain for cancer patients. In December 2013, Subsys was the most prescribed
branded transmucosal immediate-release fentanyl (TIRF) product. We
believe that its simple, one-step administration system and rapid
onset will enable further growth of our market share for and net
revenue from this unique product." The full analyst notes on INSYS
Therapeutics, Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03052014/INSY/report.pdf
--
Oxygen Biotherapeutics, Inc. Analyst
Notes
On March 4, 2014, Oxygen
Biotherapeutics, Inc. (Oxygen) announced that it has been notified
by the U.S. Food and Drug Administration (FDA) that it has
completed its review of the Company's non-clinical submission and
has lifted the clinical hold on Oxycyte®, which clears the Company
to proceed with the clinical development program in the US.
John Kelley, CEO, commented, "We are
pleased that the FDA has responded favorably to the data provided
and removed the clinical hold to allow further clinical development
of Oxycyte." Oxygen stated that it is currently enrolling patients
outside of the US in a Phase II-b study to evaluate the safety and
tolerability of Oxycyte in patients with severe non-penetrating
traumatic brain injury (STOP-TBI). The full analyst notes on Oxygen
Biotherapeutics, Inc. are available to download free of charge
at:
http://www.AnalystsReview.com/03052014/OXBT/report.pdf
--
Acorda Therapeutics, Inc. Analyst
Notes
On March 4, 2014, Acorda
Therapeutics Inc.'s (Acorda) stock increased 7.51% to end the day
at $39.09, compared to the previous
day's closing price of $36.36. The
Company's stock rose 5.17% over the past three trading days,
compared to the Nasdaq Composite which went up 0.76% during the
same trading period. The full analyst notes on Acorda Therapeutics,
Inc. are available to download free of charge at:
http://www.AnalystsReview.com/03052014/ACOR/report.pdf
--
Air Methods Corp. Analyst Notes
On March 4, 2014, Air Methods
Corp.'s (Air Methods) stock increased 7.07% to end the day at
$55.73 compared to the previous day's
closing price of $52.05. The
Company's stock gained 7.48% over the past three trading days,
compared to the Nasdaq Composite which rose 0.76% during the same
trading period. The full analyst notes on Air Methods Corp. are
available to download free of charge at:
http://www.AnalystsReview.com/03052014/AIRM/report.pdf
--
AcelRx Pharmaceuticals, Inc. Analyst
Notes
On March 3, 2014, AcelRx
Pharmaceuticals (AcelRx) reported its Q4 2013 and full-year 2013
financial results. For the quarter, the Company reported net income
of $17.8 million or $0.41 per share compared with a net loss of
$10.5 million or $0.41 per share in Q4 2012. Revenue for the
quarter totaled $27.6 million
compared to $1.7 million in Q4 2012.
For full year 2013, net loss totaled $23.4
million or $0.59 per share
compared to a net loss of $33.4
million or $1.51 per share in
full year 2012. Revenue for full year 2013 was $29.5 million compared to $2.4 million in full year 2012. Commenting on the
results, Richard King, President and
CEO of AcelRx, said, "AcelRx made strong progress in 2013 with the
successful completion of the Zalviso™ (sufentanil sublingual
NanoTab system) Phase 3 program, the filing and acceptance of the
NDA for Zalviso, the execution of a commercial partnership
agreement with Grunenthal for Zalviso that covers Europe and Australia, and agreement with FDA on a Phase 3
program for ARX-04, an investigational single-dose sublingual
sufentanil NanoTab for moderate-to-severe acute pain. As we begin
2014, we are advancing our U.S. commercial capability and preparing
for a potential Zalviso approval in third quarter of 2014." AcelRx
stated that it forecasts that quarterly R&D expenses through
the end of 2014 will be relatively consistent across all quarters
with total R&D expenses expected to be in the range of
$27 million to $29 million for the
year. The full analyst notes on AcelRx Pharmaceuticals, Inc. are
available to download free of charge at:
http://www.AnalystsReview.com/03052014/ACRX/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
AnalystsReview.com
SOURCE Analysts Review